Helios Corporation | OpenBizGraph

§01

Basic information

BASIC

Head office: 12th floor, Hibiya Mitsui Tower, 1-1-2 Yurakucho, Chiyoda-ku, Tokyo (Work Styling)
Chief executive: Toshinobu Kagi
Capital: 4,489,000,000 　(44 100 million)
Employees (non-consolidated): 82 people
Employees (consolidated): 66 people
Start date: 2011-02-24
End date

§02

Websites

1 DOMAINS

https://www.healios.co.jp/

§03

Business

1

Research, development, and manufacturing of cell drugs and regenerative medicine products.

§04

Related companies

36 COMPANIES

Company name	Group	Parent	Subsidiary	Customer	Supplier	Alliance	Bank	Shareholder
Saisei Capital Ltd. Group Parent
Saisei Ventures LLC Group Subsidiary
Procell Cure Inc. Group Subsidiary
Kyowa Hakko Kirin Co., Ltd. Group
Kirin Brewery Co., Ltd. Group
DAIICHI SANKYO COMPANY, LIMITED Group
Fujisawa Pharmaceutical Co., Ltd. Group
Novartis Pharma Co., Ltd. Group
AstraZeneca Inc. Group
Sailigen Inc. Group
Healios NA, Inc. Group Subsidiary
Nezu Asia Capital Management Group
Saisei Bioventures, L.P. Group Subsidiary
AEON Financial Service Co., Ltd. Group
Goldman Sachs Securities Inc. Group
Fidelity Investment Trust Co., Ltd. Group
モルガン銀行(現JP Morgan) Group
Astellas Institute for Regenerative Medicine Customer Alliance
iPS Academia Japan Co., Ltd. Customer Alliance
三井住友信託銀行株式会社証券代行部 Customer
AND medical group Supplier
Minaris社 Supplier
富士フイルム和光バイオソリューションズ株式会社 Supplier
株式会社デ・ウエスタン・セラピテクス研究所(DWTI) Supplier
Alfressa Alliance
CIRM Healios NA Inc. Alliance
Alfresa Corporation Alliance
アルフレッサ社 Alliance
一般社団法人AND medical 社 Alliance
Sumitomo Pharma Co., Ltd. Alliance
Osaka University Alliance
国立研究開発法人理化学研究所 Alliance
株式会RACTHERA Alliance
株式会社Akatsuki Therapeutics Alliance
RACTHERA Corporation Alliance
Athersys Shareholder

Names without a link are companies not yet registered in OpenBizGraph

§05

Network

NETWORK

§06

History

25 EVENTS

2011-02

Established Nihon Ophthalmology Research Institute (now Helios Corporation) in Higashi-ku, Fukuoka City, Fukuoka Prefecture.

2011-02

Initiating practical strategy for treating age-related macular degeneration using iPSC-derived retinal pigment epithelial cell transplantation

2012-12

Opened Tokyo office in Chiyoda-ku, Tokyo.

2013-09

Changed company name to Helios Corporation. Moved Tokyo office and headquarters to Chuo-ku, Tokyo.

2013-09

Changing the company name to Helios Co., Ltd.

2013-09

Relocating the Tokyo office and headquarters to Chuo-ku, Tokyo

2013-10

Opened research laboratory (now Kobe Research Institute) in Chuo-ku, Kobe.

2013-10

Relocating the Tokyo office and headquarters to Chuo-ku, Tokyo

2013-12

Acquired ophthalmic surgical adjunct business from Akumen Co., Ltd.

2013-12

Establishing a laboratory in Chuo-ku, Kobe (currently Kobe Research Institute)

2014-02

Established joint venture company Sailegen Co., Ltd. with Dai Nippon Sumitomo Pharma (now Sumitomo Pharma Co., Ltd.).

2014-09

Moved headquarters to Minato-ku, Tokyo.

2015-06

Listed on Tokyo Stock Exchange Mothers.

2016-01

Signed license agreement with Athersys, Inc. in the US for regenerative medicine products using MultiStem® stem cells.

2017-04

Transferred business related to BBG250-containing ophthalmic surgical adjunct to De Western Therapeutics Research Institute.

2018-02

Established subsidiary Healios NA Inc. in the US (now consolidated subsidiary).

2020-01

Commenced application of International Financial Reporting Standards (IFRS).

2020-10

Moved headquarters to Chiyoda-ku, Tokyo.

2021-01

Established fund subsidiary in regenerative medicine field including Saisei Ventures LLC, now consolidated subsidiary.

2022-04

Moved from Tokyo Stock Exchange Mothers to Growth market due to market classification review.

2023-07

Established subsidiary ProCellCare Co., Ltd. (now consolidated subsidiary).

2023-07

Establishing subsidiary ProCellCure Co., Ltd. (currently a consolidated subsidiary)

2024-04

Acquired de facto full assets of Athersys, Inc.

2024-06

Signed basic cooperation agreement and bond buyback agreement with Alfresa Co., Ltd.

2025-01

Established subsidiary Akatsuki Therapeutics Co., Ltd. (now consolidated subsidiary).

§07

News

48 ARTICLES

2026-11-12

Movie 2026 Q3 Financial Results Presentation (Supplementary Video)

2026-11-05

Poster Presentation Time for the 44th Japanese Society of Neuro-Oncology Academic Conference

Today, Helios Corporation announced the poster presentation time for the next-generation immunotherapy using Dual CAR-eNK® cells against glioblastoma at the 44th Japanese Society of Neuro-Oncology Academic Conference. The presentation is scheduled from 22:00 to 22:30, and it has been confirmed that this timing is correct as it takes place at night. Additionally, a correction was made for the venue name typo ("Arawa Onsen").

2026-10-22

Presenting Research Findings at the iPSC 20th Anniversary Symposium

During the iPSC 20th Anniversary Symposium held at the National Kyoto International Convention Center from October 20 to 22, 2026, we presented poster results on Dual CAR-eNK cells targeting EGFR and PD-L1 for glioblastoma. The poster can be viewed from this page.

2026-10-13

Dual CAR-eNK Cell Presentation at iPSC 20th Anniversary Symposium

The company will present a poster on the research results of Dual CAR-eNK® cells targeting EGFR and PD‑L1 for glioblastoma at the iPSC 20th Anniversary Symposium, held at the National Kyoto International Convention Center from October 20 to 22. For details, see the press release dated September 28.

2026-10-01

Regenerative Medicine JAPAN 2026 Exhibition and FIRM Presentation Announcement

Helios Corporation will participate in 'BioJapan 2026', 'Regenerative Medicine JAPAN 2026', and 'healthTECH JAPAN 2026', which will be held at Pacifico Yokohama from October 7 to 9. During the exhibition, we will introduce our business activities and development pipeline at our booth, and conduct a presentation exclusive to members of the Regenerative Medicine Innovation Forum (FIRM). Please refer to the press release dated September 3 for details.

2026-08-28

Helios Responds to Inquiries Following Second-Quarter Results

Since announcing its second-quarter results on August 12, 2026, Helios has been responding to inquiries from individual investors through the contact form on its website. Information about frequently asked questions is also available.

2026-08-25

Helios Co., Ltd. Relocates Tokyo Office

Helios Co., Ltd. will relocate its Tokyo office effective September 1, 2026. The new address is the 15th floor of Toranomon Hills Business Tower in Toranomon, Minato-ku, Tokyo. The company has also announced when operations will begin at the new location.

2026-08-19

Helios Publishes Q&A from FY2026 Second-Quarter Results Briefing

Helios Co., Ltd. has published the Q&A from its analyst briefing on results for the second quarter of the fiscal year ending December 2026, held on August 13, 2026. Some wording was edited without changing the content or intent.

2026-07-30

Notice to those affected by the 8th Year Reiwa Kumamoto Earthquake

Helios Corporation sincerely expresses its condolences to everyone affected by the 8th Year Reiwa Kumamoto Earthquake. We pray for the safety of the victims and their early recovery.

2026-07-29

30th Annual Meeting of the Japanese Society of Cancer Immunology and Research Presentation on Dual CAR-eNK Cells

Helios Corporation presented a poster at the 30th Annual Meeting of the Japanese Society of Cancer Immunology, showcasing research results on the development of Dual CAR-eNK cells aimed at treating malignant glioma. The presentation details are available from the English poster.